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Background: A single nucleotide polymorphism (SNP) in the
coding region of the prion protein gene (PRNP) at codon 129
has been repeatedly shown to be an associated factor to
sporadic Creutzfeldt-Jakob disease (sCJD), but additional
major predisposing DNA variants for sCJD are still unknown.
Several previous studies focused on the characterisation of
polymorphisms in PRNP and the prion-like doppel gene
(PRND), generating contradictory results on relatively small
sample sets. Thus, extensive studies are required for
validation of the polymorphisms in PRNP and PRND.
Methods: We evaluated a set of nine SNPs of PRNP and one
SNP of PRND in 593 German sCJD patients and 748
German healthy controls. Genotyping was performed using
MALDI-TOF mass spectrometry.
Results: In addition to PRNP 129, we detected a significant
association between sCJD and allele frequencies of six further
PRNP SNPs. No significant association of PRND T174M with
sCJD was shown. We observed strong linkage disequilibrium
within eight adjacent PRNP SNPs, including PRNP 129.
However, the association of sCJD with PRNP 1368 and PRNP
34296 appeared to be independent on the genotype of
PRNP 129. We additionally identified the most common
haplotypes of PRNP to be over-represented or under-
represented in our cohort of patients with sCJD.
Conclusion: Our study evaluated previous findings of the
association of SNPs in the PRNP and PRND genes in the
largest cohorts for association study in sCJD to date, and
extends previous findings by defining for the first time the
haplotypes associated with sCJD in a large population of the
German CJD surveillance study.
C
reutzfeldt-Jakob disease (CJD) is a fatal transmissible
neurodegenerative disease in humans, which can
present in acquired, familial, or sporadic forms. A
minority of CJD cases is caused by transmission from
material contaminated with infectious human CJD or bovine
spongiform encephalopathy (BSE). Around 10% of cases are
inherited and are associated with mutations in the prion
protein gene (PRNP), located on chromosome 20p12.1–3 The
majority of CJD cases (more than 90% of the CJD cases) occur
sporadically, representing the most common form of CJD
worldwide. Prion diseases such as CJD in humans, BSE in
cattle, and scrapie in goats and sheep are characterised by
spongiform degeneration, neuronal cell loss, astrogliosis, and
deposition of the scrapie isoform of the prion protein, PrPSc,
in the brain. The latter is derived through a posttranslational
conformational conversion from the cellular prion protein,
PrPC.
The aetiology of sporadic CJD (sCJD) is not known. A
common polymorphism in the coding region of the PRNP
gene at codon 129 (M129V) is a recognised genetic risk
factor. Homozygotes for methionine and to a lesser extent for
valine are over-represented in every group of sCJD examined
to date.1 4–6 In addition, this polymorphism has been shown
to modify the clinical and neuropathological phenotype of the
disease.5 In white populations, according to studies in several
countries, 37.5–45% of individuals are homozygous for
methionine and 40–51% heterozygous, and 10–15% are
homozygous for valine.6 However, PRNP M129V may not be
the sole genetic factor predisposing to the disease. In mouse
models of prion disease, inbred mouse strains with the same
genotype of the prion protein gene show notable differences
in the incubation time following experimental infection.
Detailed studies have detected several quantitative trait loci
for susceptibility to prion disease in mice, suggesting the
influence of genetic factors other than PRNP.7–9
There is growing interest in polymorphisms outside the
coding region of the PRNP gene and in other candidate genes.
Mead et al identified 56 polymorphic sites within 25 kb of the
PRNP locus, including sites within the PRNP promoter and
the PRNP 39 untranslated region. In an association study
comprising 93 sCJD patients from the UK and 652 healthy
controls from families in the UK and those registered with
CEPH (the Centre d’Etude du Polymorphisme Humain), a
significant association between an SNP upstream of PRNP
exon 1 (designated SNP 1368) and sCJD was demonstrated,
in addition to the strong susceptibility conferred by codon
129.10 However, this finding could not be confirmed by Croes
et al in a study based on a Dutch cohort.11 McCormack et al
evaluated three SNPs at position 101 bp upstream of exon 1
and at 310 bp and 385 bp downstream of exon 1 of human
PRNP, which are within or adjacent to the regulatory regions
of PRNP.12 This group suggested an association of CJD with
the polymorphisms in the regulatory regions of PRNP.
However, their data were based on a case-control study with
limited sample size (sCJD, n = 25; controls, n = 100). Thus,
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extensive studies are required for validation of the poly-
morphisms of PRNP in larger cohorts.
Another gene of interest is the prion-like doppel gene
(PRND), located 16 kb downstream of PRNP.13 PRND shares
24% coding sequence identity with PRNP, and its product, the
doppel protein (Dpl), was suggested to have biological
properties antagonistic to PrP.14 Although there have been
several published studies on the association of SNPs in PRND
with CJD, particularly PRND T174M, other studies could not
confirm this association.10 11 15–17
To evaluate the published data, which in most studies were
derived from small cohorts and in part produced conflicting
data, we investigated the association of PRNP and PRND
polymorphisms with sporadic CJD. The association study was
performed in the largest case and control cohorts to date. We
analysed the genomic DNA of 593 sCJD patients and 748
healthy controls matched for age and sex from a population
based German study (Kooperative Gesundheitsforschung im
Raum Augsburg, survey 4, (KORA S4), 2000). Analysing nine
polymorphic positions in the PRNP locus and one SNP of the
PRND, we identified two SNPs that act as possible risk factors
for sCJD in addition to the PRNP 129 polymorphism.
Additionally, we found the most common haplotypes to be
differentially distributed in healthy German controls and
German patients with sCJD.
METHODS
Subjects
CJD suspects were referred to the German CJD surveillance
unit (http://www.neuropathologie-lmu-muenchen.de/inp/
and http://www.cjd-goettingen.de/) and were clinically clas-
sified as ‘‘probable’’ or ‘‘possible’’ CJD or ‘‘other’’.18 19 The
diagnosis of ‘‘definite’’ CJD was made on post-mortem
examination using neuropathological criteria.20 DNA of
patients with ‘‘probable’’ and ‘‘definite’’ CJD were collected
and screened for pathogenic mutations in the PRNP gene. To
screen for pathogenic mutations, the coding region of PRNP
was amplified by PCR and subjected to either SSCP analysis
or direct sequence analysis (n = 316 of all analysed cases).1
Familial cases with pathogenic mutations in PRNP1 were
excluded. The remaining 593 cases, including 387 ‘‘definite’’
sCJD and 206 ‘‘probable’’ sCJD cases were enrolled in our
association study.
In total, 748 age and sex matched healthy controls were
taken from a population based German study performed in
the city and region of Augsburg (KORA S4),21 22 which is a
representative sample of the adult general population of
German nationality.
All study participants gave informed written consent
according to the Bavarian ethics committee and the ethics
committee of the Ludwig Maximilians University of Munich,
and every attempt was made to ensure anonymity of the
participants.
DNA preparation and analysis
Genomic DNA of sCJD patients was extracted in most cases
from blood or in some cases from frozen postmortem brain
tissue using commercial kits (QIAamp Blood Kit or QIAamp
Tissue Kit; Qiagen, Hilden, Germany) according to the
manufacturer’s protocols. For screening for the pathogenic
mutations, the coding region of PRNP was amplified by PCR
and subjected to single strand conformational polymorphism
(SSCP) analysis or direct sequence analysis.1 Genomic DNA
from the KORA probands was extracted from blood
leukocytes (Puregene DNA Isolation Kit; Gentra Systems,
Minnesota 55441, USA), following the manufacturer’s
instructions.
MALDI-TOF MS genotyping
Genotyping of single nucleotide polymorphisms was per-
formed using matrix assisted laser desorption ionisation-time
of flight mass spectrometry (MALDI-TOF MS) (Mass Array;
Sequenom, San Diego, CA, USA). Genomic DNA (5 ng) was
amplified by PCR using 0.1 U HotStar Taq DNA polymerase
(Qiagen). PCR conditions were 95 C˚ for 15 minutes, followed
by 44 cycles of 95 C˚ for 30 seconds, 56 C˚ for 30 seconds and
72 C˚ for 1 minute, with a final cycle of 72 C˚ for 10 minutes.
(Primer information is given in supplementary table 1, avail-
able online at http://www.jmedgenet.com/supplemental.) PCR
products were treated with shrimp alkaline phosphatase (SAP;
Amersham, Freiburg, Germany) for 20 minutes at 37˚ C to
remove excess dNTPs, followed by 10 minutes at 85˚ C to
inactivate SAP. Base extension (homogenous MassEXTEND;
Sequenom) reactions in a final volume of 10 ml contained
extension primers (supplementary table 2, available online at
http://www.jmedgenet.com/supplemental) at a final concen-
tration of 0.54 mmol/l and 0.6 U ThermoSequenase
(Amersham, Freiburg, Germany). Base extension reaction
conditions were 94˚ C for 2 minutes, followed by 40 cycles of
94˚ C for 5 seconds, 52˚ C for 5 seconds, and 72 C˚ for 5 seconds.
The final base extension products were treated with
SpectroCLEAN resin (Sequenom). Aliquots (10 nl) of the
reaction solution were dispensed onto a 384 format microarray
(SpectroCHIP; Sequenom) prespotted with a matrix of 3-
hydroxypicolinic acid. A modified Bruker Biflex MALDI-TOF
MS was used for data acquisitions from the SpectroCHIP.
Genotype calling was performed in real time with MassARRAY
RT software (version 3.0.0.4; Sequenom). For quality control,
negative controls were included in all assays. To establish
reproducibility of genotyping data, 10% of randomly selected
samples were genotyped in duplicate. Genotype frequencies at
all loci were subjected to Hardy-Weinberg equilibrium analysis.
Statistical analysis
Hardy-Weinberg equilibrium of all SNPs was determined
individually in controls using log likelihood tests. To evaluate
the non-random association of SNPs, pairwise linkage
disequilibrium (LD) statistics D9 and correlation coefficient
r2 were calculated using Haploview software (version 3.2;
Whitehead Institute for Biomedical Research; http://
www.broad.mit.edu/mpg/haploview/index.php). D9 explains
the difference in frequency between the observed and
expected number of SNP pairs. Being scaled to Dmax, it spans
the range21 to 1, and r2 is the squared correlation coefficient
between the markers.23
Differences in genotype distribution between cases and
controls were tested by the robust version of Cochran-
Armitage trend test24, adjusting for multiple testing according
to the Sidak’s method.25 Genetic association was expressed as
odds ratios (OR) for heterozygotes and homozygotes of the
rare allele versus homozygotes of the common allele, and
estimated within logistic regression models. These estima-
tions were repeated within subgroups defined by the
genotype of marker PRNP M129V (that is, homozygous MM
and VV, and heterozygous MV).
Haplotype frequencies for all observed markers were
estimated applying the EM algorithm of Excoffier and
Slatkin,26 using Arlequin software (version 2.000). Statistical
analysis was performed using SAS (version 8.2; SAS Institute,
Cary, NC, USA). The project was accomplished according the
Guter Epidemiologischer Praxis (GEP) recommendations.27
RESULTS
Association study
To reveal the association of PRNP and PRND with sCJD, we
genotyped nine SNPs in the PRNP locus and one SNP in the
PRND locus in 593 sporadic CJD patients and 748 healthy
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controls (fig 1). In addition to the SNPs in the coding region
of PRNP (PRNP A117A and PRNP M129V) and PRND (PRND
T174M), other SNPs were identified by Mead et al.10 The SNP
panel was chosen for genotyping because they are evenly
distributed across the region of interest and have been shown
to be highly polymorphic in the UK population and the
families registered with CEPH.10
The genotype frequencies of all SNPs studied achieved the
criteria of Hardy-Weinberg equilibrium in the healthy control
group (data not shown). As shown in table 1, we observed a
significant association between sCJD and the allele frequency
of the PRNP 129, confirming the predisposing role of the
PRNP 129 polymorphism in sCJD. Additionally, we detected a
highly significant association between sCJD and six other
SNPs of the PRNP locus: apart from the rare SNPs PRNP
12533 and PRNP A117A, all eight PRNP SNPs with a minor
allele frequency .15% showed significant differences in
allele frequencies between sCJD and controls. The allele
frequency of PRND T174M did not show any association with
sCJD.
To define more precisely the role of the SNPs in risk of
developing sCJD, we further investigated the association of
various genotypes and sCJD (fig 1 and supplementary
table 3). Apart from PRNP 12533 and PRND T174M, we
observed a significant association with the genotypes of all
other PRNP SNPs including the rare SNP PRNP A117A. While
PRNP 1368 and PRNP 34296 showed increased ORs in a
minor allele dose dependent manner, heterozygosity for all
other PRNP SNPs significantly decreased the risk of sCJD. The
homozygous common alleles of these SNPs (including PRNP
13436, 16987, 22976, M129V, and 28878) were associated
with higher risk of developing sCJD compared with the
homozygous minor alleles.
Linkage disequilibrium analysis
We observed strong LD in controls within eight adjacent
SNPs, from PRNP 1368 to PRNP 28878 (D9= 0.78 to 1.00,
r2 = 0.5 to 0.9), but markedly less LD to PRNP 34296
(D9= 0.33 to 0.86, r2 = 0.12 to 0.53) (fig 2). Owing to the
lower frequency of the minor alleles in PRNP 12533 (13%)
and PRNP A117A (3%), the r2 values of these less frequent
SNPs were markedly lower (r2,0.3). There was no LD
between the PRNP SNPs and PRND T174M (D9= 0.01 to 0.38,
r2 = 0.00 to 0.15).
Additional PRNP risk factors aside of the PRNP M129V
polymorphism
Given the strong LD between SNPs in the PRNP gene, the
significant association of PRNP SNPs with sCJD may be due
to hitchhiking effects with the known predisposing PRNP
M129V polymorphism. To identify possible risk factors
additional to the PRNP M129V, we performed analysis in
the PRNP M129V subgroups. This revealed a significantly
higher risk for minor allele homozygotes of PRNP 1368 in the
subgroup of PRNP codon 129 MM homozygotes (OR = 1.7,
95% confidence interval (CI) = 1.002 to 2.931) (table 2). In
the same subgroup, only the PRNP 34296 minor allele showed
a trend for association with sCJD (OR = 1.5, 95% CI = 0.94 to
2.45), independent of the PRNP M129V polymorphism. All
other SNPs did not show any association with sCJD
independent of the genotype of marker PRNP M129V.
SNP haplotypes
In the region between PRNP 1368 and PRNP 34296, we
revealed the existence of 188 complete and incomplete
haplotypes. As shown in table 3, five major PRNP haplotypes
showed a frequency .5% in all cases and controls,
representing 62% of all estimated haplotypes. Two of these
five haplotypes (haplotypes 4 and 5 in table 3), which only
differed by the allele of the marker PRNP 34296 at the far end
of the screen region, were significantly over-represented in
sCJD patients. The remaining three haplotypes (haplotypes
1–3 in table 3) , which differed again at marker PRNP 34296
and additionally at PRNP 28878, were significantly under-
represented in patients.
DISCUSSION
The identification of genetic risk factors in sporadic CJD is
important for our understanding of possible pathogenic
mechanisms and the susceptibility to the disease. Efforts
have been made to identify genetic risk factors other than the
well described PRNP M129V polymorphism. Several previous
studies focused on the characterisation of SNPs in PRNP and
PRND genes, generating contradictory results on relatively
small sample sets. This led us to evaluate a panel of nine
SNPs in the PRNP locus and one SNP in the PRND gene in a
large German sCJD cohort and population based healthy
controls.
We found a significant association of sCJD with seven of
nine PRNP SNPs studied, including PRNP 1368, 13436, 16987,
22976, M129V, 28878, and 34296. In agreement with
previous studies, individuals with homozygosity of both
methionine and valine for PRNP M129V showed an increased
risk in sCJD. We further found that the association of PRNP
1368, located ,24 kb upstream of the coding region PRNP,
was independent of the genotype of PRNP M129V. This result
confirmed a previous study that compared sCJD cases in the
UK with either the CEPH families from France or healthy UK
population.10 However, this finding disagrees with the result
from an earlier study based on a Dutch population.11 The
difference between these studies and the Dutch study may be
due to differences in the ethnic populations, or more likely,
may be influenced by the small sample size in the Dutch
study (sCJD n = 23; controls n = 83). In addition to PRNP
1368, we also found that the homozygous minor allele of
PRNP 34296, an SNP located ,8 kb downstream of the 39
coding region of PRNP, tended to increase the susceptibility to
sCJD of individuals homozygous for methionine at PRNP
M129V. It should be noted that the power of this study is
limited owing to lower sample size within the heterozygous
PRNP M129V group (96 patients versus 324 control pro-
bands) and the homozygous valine group (78 patients versus
99 control probands). The power to detect genotype related
risks in these two PRNP M129V subgroups for a marker with,
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Figure 1 Association of genotypes of PRNP SNPs with sCJD. Estimated
odds ratios of heterozygous (SNP ID-1) and homozygous (SNP ID-2)
minor alleles versus the homozygous common allele, and 95%
confidence intervals are shown. No homozygous minor allele was
observed in PRNP A117A. Detailed information is given in
supplementary table 3 (available online at http://www.jmedgenet.com/
supplemental). * p = 0.01, ** p = 0.001, *** p,0.0001.
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for example, an allele frequency of 0.3, is only 44% and 28%,
respectively. Therefore, larger studies are needed for further
evaluation of the association of PRNP SNPs with sCJD,
independent of PRNP M129V.
Attention has been paid to the genetic variances in the
regulatory region of PRNP, as there is evidence in animal
models that PrP gene expression levels influence the
susceptibility to prion diseases and the incubation time of
disease. Overexpression of the PrP gene in transgenic animals
demonstrated shortening of incubation time of animals
inoculated with prions,28 while mice heterozygous for a
disrupted PrP gene and expressing only half of the normal
PrP have prolonged incubation times following infection,
whereas PRNP knockout mice are completely resistant to
prion disease. Moreover, Hardy et al stated that those who
express high levels of prion protein and are homozygous at
codon 129 are most susceptible to disease, and that in
diseases where protein deposition is part of the process,
genetic variability in the promoter of the gene should be
considered as a factor influencing risk of sporadic diseases.29
Therefore, the underlying mechanism of association of SNP
1368, located in the promoter region of PRNP, with sporadic
prion diseases may possibly originate in high expression of
the prion protein gene. However, this hypothesis has to be
proven by functional analyses.
In addition, our data clearly show the independence of
association of SNP1368 with sCJD from that of M129V with
sCJD. This is in line with Hardy’s ‘‘law of mass action’’,
which states that the concentration of the pathogenic protein
might only cause the initiation of the disease through the
formation of a pathogenic template.30 After initiation, the
proteins adopt the same conformation of the template. This
process is probably facilitated by homozygosity at codon 129,
due to symmetry considerations in prion-prion interactions.
This process becomes self propagating. Thus, the latter
pathogenesis may be largely independent of prion protein
concentration.
Previous work has identified several regulatory regions of
human PRNP, located about 273 bp from exon 1,12 31 and in
the intronic region between 292 and 625 bp downstream of
exon 1.12 McCormack et al evaluated three SNPs in these
regions in an association study with small sample sizes
(controls n = 100, CJDs n = 25), and suggested that these
SNPs, including an SNP corresponding to PRNP 12533 in the
present study may be risk factors for CJD. However, we could
not confirm a significant association between PRNP 12533
and sCJD. In addition, PRNP 13436, an SNP in the intronic
regulatory region, did not show a significant association with
sCJD, independent of PRNP M129V. Our data suggest that
the SNPs in these previously defined regulatory regions may
not function as additional risk factors to sCJD.
In the present study, we demonstrated the existence of five
major haplotypes of PRNP, determined by eight SNPs. It
should be noted that the markers PRNP 12533 and PRNP
A117A showed the same allele in all five major haplotypes,
while markers PRNP 28878 and PRNP 34296 showed different
alleles within the under-represented and over-represented
haplotypes. The remaining five markers (PRNP 1368, 13436,
16987, 22976 and M129V) distinguished the under-repre-
sented and over-represented haplotypes. Therefore, a predis-
posing role of the region spanned by these five SNPs is highly
probable. This region is 24 491 bp in length, and shows
strong LD as described above. The identified major haplo-
types showed strong consistency with the findings in the UK
study,10 both in genotypes and in their distribution in sCJD
and controls. For example, the two most common haplotypes
in the UK study (haplotypes A and B; table 3) coincide with
the two most common haplotypes in the present study
(haplotypes 1 and 5), suggesting that German PRNP
Table 1 SNP allele frequencies in sCJD cases and healthy controls
SNP ID
Sample size (n) MAF (%) p
sCJD Controls sCJD Controls Marker Family
PRNP 1368 (T/C) 507 740 50 40 ,0.001 ,0.001
PRNP 12533 (C/G) 534 740 14 13 0.651 1.000
PRNP 13436 (T/C) 542 726 24 39 ,0.001 ,0.001
PRNP 16987 (T/G) 588 746 18 32 ,0.001 ,0.001
PRNP 22976 (A/G) 570 697 15 28 ,0.001 ,0.001
PRNP A117A (A/G) 575 744 1 3 0.035 0.454
PRNP M129V (A/G) 582 722 22 36 ,0.001 ,0.001
PRNP 28878 (T/C) 589 742 13 23 ,0.001 ,0.001
PRNP 34296 (A/G) 585 741 45 37 ,0.001 ,0.001
PRND T174M (C/T) 582 740 49 50 0.662 1.000
The significance of association results was examined by the Cochran-Armitrage trend test (marker wise) and the p
values adjusted for multiple testing (family wise) according to Sidak.25
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Figure 2 SNP location and pairwise linkage disequilibrium between
genotyped variants in PRNP and PRND. The top indicates the physical
SNP locations relative to the exons of the PRNP and PRND locus on
chromosome 20p12. SNPs in coding regions are indicated by the
location of the codons and exchange of amino acids. All other SNPs are
designated by their location on clone U29185. The base exchange in
each SNP is given in parentheses. The first letter represents the major
allele and the second the minor allele. Exons of PRNP and PRND genes
are highlighted by arrows. Shading of the diamonds represents
magnitude and significance of the pairwise r2 between the two SNPs,
defined by the top left and the top right sides of the diamond, with black
reflecting high r2 (r2.0.8) and white reflecting low r2 (r2,0.2).
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genealogy can also be characterised by these two proposed
major haplotype branches.
Recently, attention has also been focused on PRND and the
association of SNPs at the PRND locus with CJD. However,
the results of earlier studies are contradictory. Studies on
PRND T174M either showed no significant relationship,10 16 17
or a significantly increased risk for those heterozygous15 or
homozygous for methionine.11 The present work showed
neither significant association of different genotypes of PRND
T174M with sCJD, nor strong linkage disequilibrium between
the PRNP SNPs and PRND T174M, confirming the finding of a
previous study based on UK and French populations.10 This
result suggests a less important role of PRND T174M in prion
disease pathogenesis. However, PRND cannot be excluded as
a possible candidate gene. According to our study and a
previous study,10 PRNP 34296 demonstrated a significant
association with sCJD and was located in a region of strong
LD, also including SNPs upstream of PRND.10 Thus, associa-
tions of other genetic variants of PRND with sCJD, especially
those upstream of PRND, independent of PRND T174M, may
be possible.
In conclusion, we identified a significant association of
seven PRNP SNPs with sCJD. Most of these associations are
hitchhiking effects with the known predisposing effect of the
PRNP M129V polymorphism. We confirmed the results of a
previous study indicating that PRNP 1368 is associated with
sCJD, independent of PRNP M129V. In addition, our results
suggest that PRNP 34296 may also be an additional
independent risk factor. Furthermore, we detected a strong
LD region from PRNP 1368 to PRNP 28878, and identified the
major haplotypes of PRNP SNPs that were over-represented
or under-represented in sCJD cases. The cases and controls
analysed in this study are the largest cohorts for association
study in sCJD to date. These cohorts provide a basis for the
association studies of further genetic variants in candidate
genes involved in the susceptibility and pathogenesis of sCJD.
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Table 2 Odds ratios of examined SNPs in PRNP and PRND in the subgroup of PRNP 129
methionine homozygote patients
SNP ID
Genotypes
compared OR 95% CI p
PRNP 1368 (T/C) C/T v T/T 1.498 0.890 to 2.521 0.1281
C/C v T/T 1.714 1.002 to 2.931 0.0491
PRNP 12533 (C/G) C/G v G/G 0.828 0.576 to 1.191 0.3084
C/C v G/G 0.572 0.162 to 1.935 0.3689
PRNP 13436 (T/C) C/T v T/T 0.767 0.480 to 1.227 0.2684
C/C v T/T ND — —
PRNP 16987 (T/G) G/T v T/T 0.756 0.304 to 1.880 0.5476
G/G v T/T n.d — —
PRNP 22976 (A/G) A/G v A/A 0.540 0.049 to 5.990 0.6157
G/G v A/A ND — —
PRNP A117A (A/G) A/G v A/A ND — —
G/G v A/A ND — —
PRNP M129V (A/G) A/G v A/A ND — —
G/G v A/A ND — —
PRNP 288778 (T/C) C/T v T/T 0.567 0.051 to 6.293 0.6443
C/C v T/T ND — —
PRNP 34296 (A/G) A/G v A/A 1.073 0.705 to 1.632 0.7435
G/G v A/A 1.519 0.942 to 2.447 0.0862
PRND T174M (C/T) C/T v C/C 0.921 0.616 to 1.379 0.6903
T/T v C/C 0.886 0.554 to 1.417 0.6125
Odds ratios of heterozygous and homozygous minor allele versus homozygous common allele, and 95%
confidence intervals (CI) are given. ND, genotypes were not detectable in the subgroup of PRNP 129 MM
homozygotes.
Table 3 Major haplotypes of PRNP SNPs and their frequencies in cases and controls
Over-represented
in:
Haplotypes of PRNP Frequency
p1368 12533 13436 16987 22976 A117A M129V 28878 34296 Cases Controls
Controls 1 T C C G G A G C A 9.08% 16.46% ,0.00001
2 T C C G G A G T A 2.36% 5.16% 0.0002
3 T C C G G A G C G 1.69% 4.17% 0.0002
T C C G G A G C — Haplotype A in Mead et al10
Cases 4 C C T T A A A T A 13.99% 10.56% 0.007
5 C C T T A A A T G 33.03% 26.26% 0.0001
C C T T A A A T — Haplotype B in Mead et al10
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